GlycoMimetics (GLYC) Tops Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022
November 9, 2022 7:00 AM ESTU.S. Food and Drug Administration (FDA) clears protocol amendment to conduct an interim utility analysis of pivotal Phase 3 study of uproleselan in relapsed/refractory acute myeloid leukemia (AML) Blinded pooled survival data show patients in the Phase 3 study continue to live longer than historically expected; final survival events trigger now projected around year-end 2023 Independent Data Monitoring Committee (DMC) to determine by end Q1 2023 if the study should continue as planned or be immediately unblinded for full analysis if efficacy data is compelling Cash runway extended to the end of... More
